{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000603","form_type":"8-K","ticker":"CYDY","cik":"0001175680","company_name":"CytoDyn Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.567737+00:00","generated_at":"2026-06-06T15:45:48.255507+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytoDyn appoints Jacob Lalezari as permanent CEO, names Mitchell Cohen interim CFO","bullets":["Jacob Lalezari appointed CEO effective Jan 26, 2024; previously interim CEO since Nov 2023.","Base salary $400K, target annual bonus 40%, option grant of 3M shares vesting over 4 years.","Antonio Migliarese resigns as CFO effective Jan 31, 2024; last day Feb 15.","Mitchell Cohen appointed interim CFO effective Feb 1, 2024; independent contractor via Rapid Deployment."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000603","json":"https://secwatch.observer/filing/0001558370-24-000603.json","markdown":"https://secwatch.observer/filing/0001558370-24-000603.md","text":"https://secwatch.observer/filing/0001558370-24-000603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/cydy-20240123x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:45:48.255507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c2722a3a3","claim":"Jacob P. Lalezari was appointed as Chief Executive Officer at CytoDyn Inc..","evidence_excerpt":"On January 26, 2024, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s Chief Executive Officer and will serve as its principal executive officer, effective as of January 26, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"31c7c4fec4","claim":"Mitchell Cohen was appointed as Interim CFO at CytoDyn Inc..","evidence_excerpt":"On January 10, 2024, the Company entered into an agreement with Rapid Deployment LLC d/b/a InterimExecs (“InterimExecs”), under which Mitchell Cohen will serve as the Company’s Interim CFO, effective February 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim CFO"}],"fact_type":"executive_change"},{"claim_id":"9a5c847503","claim":"Antonio Migliarese resigned as CFO at CytoDyn Inc..","evidence_excerpt":"On January 23, 2024, Antonio Migliarese informed the Company that he would be resigning from his position as CFO, effective January 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837024000603/0001558370-24-000603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"CFO"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}